OncLive News Network: On Location at ESMO 2022 - Episode 2

Gathering Insights in Gynecologic, Lung, and GI Cancers From ESMO 2022: Drs Matulonis, Peters, and Janjigian

September 11, 2022

Caroline Seymour, Solange Peters, MD, PhD, Ursula A. Matulonis, MD, Yelena Y. Janjigian, MD

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

EP. 1: Advances in Breast and Gastrointestinal Cancers at ESMO 2022: Drs Rugo and Abou-Alfa

Now Viewing

EP. 2: Gathering Insights in Gynecologic, Lung, and GI Cancers From ESMO 2022: Drs Matulonis, Peters, and Janjigian

EP. 3: Breaking Down Treatment Developments in Breast and Genitourinary Cancers From ESMO 2022: Drs O'Shaughnessy and Choueiri

OncLive^® will be LIVE with OncLive^® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Today-

We are reporting from the 2022 ESMO Congress!

Get ready for highlights of some of the top news presented each day during the meeting—and soon we’ll speak with Dr Ursula Matulonis to highlight exciting findings in gynecologic cancer, Dr Yelena Janjigian to provide insight on key trials in gastrointestinal cancer, and Dr Solange Peters to share perspective on some of the congress highlights.

Welcome to OncLive News Network! I’m Caroline Seymour.

Long-term follow-up from the phase 3 EMPOWER-Cervical1 trial showed a clinically meaningful and statistically significant improvement in overall survival versus chemotherapy, at 11.7 months versus 8.5 months, in patients with recurrent or metastatic cervical cancer following frontline platinum-based chemotherapy.

In 7-year follow-up findings of the phase 3 SOLO-1 trial, two years of olaparib maintenance therapy elicited a long-term overall survival benefit versus placebo in patients with newly diagnosed, BRCA-mutant, advanced ovarian cancer, with a hazard ratio of 0.55.

Trastuzumab deruxtecan continued to demonstrate substantial clinical benefit and a tolerable safety profile as second- or later-line therapy in Western patients with HER2-positive unresectable or metastatic gastric or gastroesophageal cancer, with a 1-year overall rate of 50.6%.

Finally, results from the KRYSTAL-1 trial indicated that adagrasib was well tolerated as monotherapy and in combination with cetuximab in heavily pretreated patients with KRAS G12C–mutated CRC, leading to an ORR of 19% and 46%, respectively.

Please be sure to check out more of our coverage from the 2022 ESMO Congress at OncLive.com.

That’s all for today. Tomorrow, we’ll sit down with Drs Joyce O’Shaughnessy and Toni Choueiri who will share their perspectives on breaking research in breast and genitourinary cancers.

Thank you for watching OncLive News Network: On Location, I’m Caroline Seymour.